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kappa index.
Results: 100 patients were analysed. With the VN 7% of patients were HR to ASA
(ARU> 550) and 41% to PFA (TO <193S). 3% were HR to aspirin with both methods.
4% were HR to ASA with the VN system but sensitive to it with the analyser PFA.
38% were sensitive to ASA with the VN test and HR with the PFA and 55% were ASA
sensitive with both methods. The Spearman correlation coefficient between both
methods of measurement of was r2= 0.09 (p = 0.35) and the Kappa index value =
0.0062 (p = 0.91).
Conclusion: 1. The prevalence of HR to ASA in type 2 diabetic patients treated with
PCI using XienceV drug-eluting stent implantation and dual antiplatelet therapy is
highly variable depending on the measurement method used. 2. There is no
concordance or correlation between both methods of measurement, and therefore its
use should be restricted to clinical research, limiting the application of these tests in
clinical practice.
TCT-158
Inhibition of Platelet Aggregation by Prostaglandin E1 (PGE1) May Be
Attenuated in Diabetic Patients During Therapy with Clopidogrel
Rolf P Kreutz, Perry Nystrom, Yvonne Kreutz, Jiao Miao, Richard Kovacs, David
Flockhart, Zeruesenay Desta, Yan Jin
Indiana University School of Medicine, Indianapolis, IN
Background: Diabetes mellitus (DM) is associated with increased platelet activation
and reduced platelet inhibition by clopidogrel. PGE1 increases adenyl cyclase activity
in platelets and increases cyclic AMP concentrations. PGE1 is an endogenous platelet
inhibitor and its effects are additive to exogenous P2Y12 inhibition. The VerifyNow
(VN) P2Y12 point of care assay includes PGE1 at 22nM to suppress P2Y1 receptor
signaling along with ADP.
Methods: Subjects with established coronary artery disease and prior coronary stenting
who were taking clopidogrel 75mg daily for >14 days were enrolled (n=96). Diabetic
(n=34) were compared with non-diabetic subjects (n=62). Light transmittance
aggregometry (LTA) was performed at various concentrations of ADP with and without
the addition of PGE1, as well as VN P2Y12 assay.
Results: Residual on-treatment platelet aggregation induced by 5, 10, and 20μM ADP
was not significantly different between subjects with and without DM. Addition of
22nM and 88nM PGE1 to 20μM ADP resulted in a significant reduction of maximal
platelet aggregation (MPA). Residual platelet aggregation with PGE1 was significantly
higher in subjects with DM as compared to non-diabetics. VerifyNow P2Y12 PRU was
higher in subjects with DM as compared to non-diabetics (table). VN P2Y12 reactivity
correlated with MPA induced by ADP 20μM (r=0.69) and ADP 20μM & PGE1 22nM
(r=0.61)
Conclusion: Addition of PGE1 to ADP was associated with higher residual MPA in
subjects with DM as compared to non-diabetics. On treatment MPA induced by ADP
alone was not significantly different between subjects with and without DM measured
by LTA. Addition of PGE1 to ADP agonist platelet assays may result in a higher
proportion of subjects with DM being classified as non-responders. Impaired inhibitory
response to PGE1 may contribute to the high platelet reactivity phenotype in subjects
with DM.
TCT-159
Recovery of Platelet Function After a Loading Dose of Prasugrel or Clopidogrel
in Patients With Coronary Artery Disease
Isabell Bernlochner2, Tanja Morath2, Patricia B Brown1, Chunmei Zhou1, Brian A
Baker3, Joseph A Jakubowski1, Kenneth J Winters1, Adnan Kastrati2, Dirk Sibbing2
1Eli Lilly and Company, Indianapolis, IN; 2Deutsches Herzzentrum München,
München, Germany; 3Daiichi Sankyo, Inc., Parsippany, NJ
Background: Prasugrel is associated with higher levels of platelet inhibition compared
to clopidogrel, which may result in longer times for platelet P2Y12 receptor function
to recover following drug cessation. The aim of this study was to assess the time to
recovery of platelet function in patients with coronary artery disease following
administration of a prasugrel or clopidogrel loading dose (LD).
Methods: Recovery of platelet function after LD was defined as occurring on the first
day that VerifyNow™ P2Y12 reaction units (PRU) were ≤60 below pre-drug values
and remained in this range. The percentage of subjects (n=21) who recovered over
time (3, 5, 7, 9, and 11 days) following 30 or 60 mg prasugrel or 600 mg clopidogrel
with aspirin was assessed by measurement of PRU. The relationship between inhibition
of platelet function at 24 hours post LD to time of recovery was also evaluated.
Results: Pre-drug, mean PRU was 337.6, 308.2, and 323.0 for prasugrel 60 mg,
prasugrel 30 mg, and clopidogrel 600 mg, respectively. At 24 hours post-LD, mean
PRU were lowest for prasugrel 60 mg (32.5), followed by prasugrel 30 mg (70.0), and
clopidogrel 600 mg (193.0). Recovery for all prasugrel-treated subjects occurred from
Days 5-9, while recovery for clopidogrel-treated subjects occurred from Days 3-7
(Figure 1).
Conclusion: Time for platelet function to return to baseline reflected the extent of
platelet inhibition at 24 hours post-LD. Prasugrel-treated subjects required a longer
time for recovery compared with clopidogrel.
TCT-160
High On-treatment Platelet Reactivity Measured by Various Platelet Function
Tests: Is the Current VASP-PRI Cutoff Too Low?
Young-Hoon Jeong1, 2, Kevin P. Bliden1, Udaya S. Tantry1, Yongwhi Park2, Jin-Yong
Hwang2, Paul A. Gurbel1
1Cardiac Catheterization Laboratory, Sinai Center for Thrombosis Research,
Baltimore, MD; 2Gyeongsang National University Hospital, Jinju, Republic of
Korea
Background: High on-treatment platelet reactivity (HPR) to ADP measured by
multiple methods has been linked to adverse post-PCI clinical event occurrence. The
correlation of HPR cutoffs is still a matter of debate, since the predictive value and
HPR group size are different depending on platelet function assays. To determine the
comparable cutpoint, we correlated cutpoints for HPR determined by various assays
in the same patient cohort.
Methods: Platelet measures [5μM ADP-induced light transmission aggregation
(LTA:5μMADP); P2Y12 reaction units by VerifyNow (PRU), and platelet reactivity
index by VASP assay (PRI)] were evaluated (n=936 pairs, cohort I) in stable CAD
patients during P2Y12 receptor inhibitor treatment. These assays also performed in
PCI-treated patients receiving standard aspirin and clopidogrel therapy (n=584, cohort
II). The HPR cutpoints were defined as LTA:5μMADP >46%, PRU >235, and PRI
>50%.
Results: In the stable CAD patients, LTA:5μMADP showed significant correlations
with PRU and PRI (r ≥0.688). In ROC curve analysis using the cutpoint of
LTA:5μMADP (>46%), the matched values of PRU and PRI were >234 (AUC 0.943,
p<0.001, sensitivity 87.3% and specificity 87.8%) and >60% (Figure A). Among PCI-
treated patients, the prevalence of HPR was highest based on PRI >50% (69%)
compared with other criteria (≤55%). The comparable values for LTA:5μMADP >46%
were PRU >235 (AUC 0.850, p<0.001, sensitivity 85.3% and specificity 70.4%) and
PRI >59% (Figure B).
Conclusion: The published cutoff values for HPR by LTA:5μMADP and PRU were
well correlated, whereas published PRI >50% cutoff value may overestimate the risk
of HPR. Updated cutoff of PRI > 60% may better stratify the risk for HPR and can be
used in future trials.
TCT-161
Anemia is a major predictor of decreased platelet response to clopidogrel
following coronary stenting
Catalin Toma, Firas E Zahr, Diego Moguillansky, Nicole Lemieux, Roy Semaan,
Rosalyn J Rapsinski, Joon S Lee, Suresh Mulukutla, Oscar C Marroquin
University of Pittsburgh Medical Center, Pittsburgh, PA
Background: A decreased response to clopidogrel as assessed by platelet aggregation
testing following percutaneous coronary interventions (PCI) is a predictor of recurrent
ischemic events. Significant intra-individual variability in platelet aggregation on repeat
testing has been reported.
Methods: To understand this variability, we examined the clinical and laboratory
elements linked to high residual platelet reactivity (HRPR) in 255 consecutive patients
tested at least 12 hrs following the PCI, using both light transmission aggregometry in
response to 5μM ADP (LTA) and the Accumetrics VerifyNow P2Y12 assay
(VNP2Y12). HRPR was defined based on previously validated cutoffs (>46% for LTA,
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>236PRUs for VNP2Y12.
Results: Using univariate logistic regression, several variables were associated with
HRPR (anemia, female gender, history of hypertension and absence of a clopidogrel
loading dose for LTA, and anemia, female gender, history of hypertension, CVA,
diabetes or hypercholesterolemia, kidney disease and concurrent use of proton pump
inhibitors for VNP2Y12). On multivariate analysis however, the only variable
independently associated with HRPR with both assays was laboratory-defined anemia,
present in 37.3% of the patients. The prevalence of HRPR by LTA was 34.3% amongst
anemic patients and 15.6% of the patients with normal hemoglobin levels, and 59.8%
versus 25.9% respectively by VNP2Y12 (p<0.005 in both cases). In a subgroup of 50
patients testing was done both before and after the clopidogrel loading dose. At baseline
there were no differences in the platelet aggregation with either assay. The absolute
inhibition of platelet aggregation to ADP following the clopidogrel load was
significantly less in anemic patients compared to patients with normal hemoglobin
levels, as measured by both assays (delta residual aggregation by LTA of 15.8±5.8%
vs 28.8±3.2%, p<0.05, and delta PRU by VNP2Y12 of 56.5±35.5 PRUs vs 145.0±14.2
PRU’s, p<0.01 respectively).
Conclusion: Anemia is a novel major contributor to HRPR on clopidogrel and may
explain some of the intra-individual variability of platelet aggregation testing.
TCT-162
Ticagrelor Enhances Adenosine-induced Coronary Vasodilatory Responses in
Humans—a Randomised, Double-Blind, Placebo-Controlled, Crossover, Single
Centre Study Using Transthoracic Color Doppler Echocardiography
Li-Ming Gan1, Ann Wittfeldt2, Håkan Emanuelsson1, Sven Nylander1, Magnus
Andersson1
1AstraZeneca R&D, Mölndal, Sweden; 2Institute of Medicine, Sahlgrenska
University Hospital, Gothenburg, Sweden
Background: Ticagrelor, the first reversibly binding oral P2Y12 antagonist, has a
clinical profile consistent with a secondary pharmacologic effect related to adenosine.
This study explored whether ticagrelor can augment increases in coronary blood flow
velocity (CBFV) induced by adenosine, and if any increase can be inhibited by
theophylline, an adenosine receptor antagonist.
Methods: 40 healthy male subjects (18-40y) underwent 2 treatments, 180mg ticagrelor
or placebo, separated by a wash-out. CBFV was measured using transthoracic color
Doppler echocardiography. Following 3.5MHz color Doppler mapping of the mid-
distal segment of the left anterior descending coronary artery, CBFV was measured
using 1.75MHz pulsed wave spectral Doppler. During each treatment period a step
wise increased adenosine infusion ladder, 0, 50, 80, 110 and 140μg/kg/min, was given
3x: predose; 2h after administration of 180mg ticagrelor or placebo; after a 20-min
infusion of 5mg/kg theophylline. CBFV was measured at each adenosine dose.
Complete CBFV signals were obtained in 38/40 subjects.
Results: Adenosine dose-dependently increased CBFV during all dose ladders.
Ticagrelor significantly enhanced the adenosine-induced CBFV responses compared
to placebo as the area under the CBFV vs adenosine dose curve increased significantly,
15% (CI:9%;21%) vs 4% (CI:-1%;10%); p=0.008. The greatest effect on CBFV was
observed at 80μg/kg/min adenosine; ticagrelor 72.5±32.9cm/s, placebo 54.0±29.3cm/s.
Theophylline inhibited the adenosine-induced vasodilatory responses in a similar way
in both groups, indicating the augmented response after ticagrelor dosing was mediated
via the adenosine receptors and not through a unique pathway.
Conclusion: Ticagrelor enhanced coronary vasodilatory response by an adenosine-
dependent mechanism. This suggests that augmentation of the physiological response
to endogenous adenosine may be a mechanism that, together with the primary
antiplatelet action, might contribute to the clinical profile of ticagrelor.
TCT-163
Accelerated Platelet Inhibition after Switching with Hydrophilic Statin in
Patients with Increased Platelet Reactivity During Atorvastatin and
Clopidogrel Coadministration (ACCEL-STATIN) study: a randomized,
parallel-group trial
Young-Hoon Jeong1, 2, Yongwhi Park1, Seok-Jae Hwang1, Choong Hwan Kwak1, Jin-
Yong Hwang1
1Gyeongsang National University Hospital, Jinju, Republic of Korea; 2Cardiac
Catheterization Laboratory, Sinai Center for Thrombosis Research, Baltimore, MD
Background: Because CYP3A4 enzyme activity contributes to clopidogrel
metabolism, CYP3A4-metabolized statin may affect the pharmacokinetics and
pharmacodynamics of clopidogrel. We performed this study to assess the influence of
non-cytochrome (CYP) 3A4-metabolized statin switch on platelet inhibition among
patients receiving clopidogrel and atorvastatin coadministration.
Methods: We enrolled 50 patients with increased platelet reactivity [20μM ADP-
induced maximal platelet aggregation (PA) >50%] receiving chronic atorvastatin
(10mg/d) and clopidogrel (75mg/d) plus aspirin (100mg/d) treatments after
percutaneous coronary intervention (PCI) (≥6 months). They were randomly assigned
to switch atorvastatin with either rosuvastatin 10 mg/d (n=25) or pravastatin 20 mg/d
(n=25). Platelet reactivity was assessed before and after 15-day switch treatment with
conventional aggregometry and the VerifyNow P2Y12 assay. Primary endpoint was
absolute change of ADP-induced maximal PA. High on-treatment platelet reactivity
(HPR) was defined as 5μM ADP-induced maximal PA > 46% or P2Y12 reaction unit
(PRU) >235.
Results: All patients completed the study without specific events. Absolute changes
of 20 and 5μM ADP-induced maximal PAs were significant after switch with non-
CYP3A4-metabolized statin [66.9±8.4% to 60.3±15.0%, mean delta 6.6%, 95%
confidence interval (CI) 3.2~10.1%, p <0.001; 52.7±10.7% to 46.4±16.7%, mean delta
6.3%, 95% CI 2.5~10.2%, p <0.001, respectively). Likewise, ADP-induced late PAs
and PRU were significantly decreased after switch (p ≤0.002). HPR was also overcome
in about one third of the patients. The magnitude of this effect was similar after the
switch with rosuvastatin or pravastatin. Compared with patients who received calcium
channel blocker (CCB) (n=9), those who did not take CCB (n=41) showed significantly
enhanced antiplatelet effect of clopidogrel.
Conclusion: Among PCI-treated patients with increased platelet reactivity during
clopidogrel and atorvastatin coadministration, switch with non-CYP3A4-metabolized
statin can enhance the antiplatelet effect of clopidogrel and decrease the risk of HPR,
especially in patients without CCB. These results can support pharmacological
interactions between clopidogrel and CYP3A4-metabolized drugs.
TCT-164
Impact of Bleedings on Prasugrel Adherence in Real World Patients
Guido Parodi, Benedetta Bellandi, Francesco Venditti, Nazario Carrabba, Renato
Valenti, Angela Migliorini, Silvia Grassellini, Erica Ramazzotti, David Antoniucci
Careggi Hospital, Invasive Cardiology, Florence, Italy
Background: Recent guidelines recommend the use of aspirin and prasugrel in patients
with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention
(PCI). However, prasugrel use has been evaluated only in randomized trials. There are
no data regarding prasugrel in the real world setting.
Methods: A total of 298 consecutive patients aged 68±10 years (31% ≥75 years)
underwent stent implantation and received prasugrel therapy. Indications to prasugrel
therapy were: 1) ST-elevation acute myocardial infarction (STEMI; 41%), 2) drug-
eluting stent (DES) implantation in diabetics (24%), 3) stent thrombosis (3%), 4) left
main DES implantation (6%), and 5) ACS or DES implantation in patients with high
residual platelet reactivity on clopidogrel therapy (26%). All patients received a 60 mg
prasugrel loading dose. Patient aged ≥75 years and with ≤60 kg of body weight
received a maintenance dose of 5 mg/day (10 mg/day for all the other patients). Follow-
up data, including adherence to prasugrel therapy, were collected by telephone
interviews or outpatient visits. Minimal follow-up length was 6 months (mean 9±3
months).
Results: Major, minor, and minimal bleedings (TIMI criteria) occurred in 2.7%, 4.7%,
and 15.1% of the enrolled patients. The most frequent minimal bleeding event was
epistaxis. Only 8 (2.7%) patients permanently discontinued prasugrel therapy due to
bleeding events (n=4), possible side effects (n=2), or medical decisions not associated
with bleeding or side effects (n=2). Fourteen (4.7%) patients temporarily discontinued
prasugrel (average 6.5 days) mainly due to surgical procedures. No definite or probable
stent thrombosis occurred, while 3 patients had a de-novo myocardial infarction, and
1 an ischemic stroke. There were 11 deaths, due to heart failure or refractory
cardiogenic shock (9), pulmonary embolism (1), and cancer (1).
Conclusion: In the clinical practice, major and minor bleeding event rates associated
with prasugrel therapy are comparable with those reported in controlled randomized
trials. Minimal bleeding event rate is higher than reported, but it seems not to impact
on adherence to treatment.
TCT-165
Response to Prasugrel in ST Elevation Myocardial Infarction Patients: is it as
Rapid as we Expected?
Frédéric Casassus, Lionel Leroux, Chloe James, Sali Sidibe, Agnalys Desplantes,
David Naibo, Benjamin Seguy, Pierre Chevallereau, Pierre Coste
hospital of Haut-Leveque, Pessac, France
Background: A pre-hospital 60mg loading dose of prasugrel can be administered in
patients with ST elevation Myocardial Infarction (STEMI) treated with primary
percutaneous coronary intervention (pPCI). Whether such a loading dose of prasugrel
is efficient in inhibiting platelet activity when pPCI is started is unknown. Using the
P2Y12 Verifynow assay (Accumetrics, San Diego, USA), we assessed prasugrel
responsiveness in the beginning of the pPCI in STEMI patients.
Methods: Our study is a single center observational study. During a 6 months period,
we prospectively analyzed STEMI patients. We compared this group to Non-STEMI
patients (NSTEMI) group, treated in a similar way, with same delay between prasugrel
administration and Verifynow assessment. A pre-defined cut-off Platelet Reactivity
Unit (PRU) > 235 was considered as suboptimal inhibition.
Results: Forty five STEMI and 20 NSTEMI patients were included. Baseline
characteristics were similar in both groups, including the mean time between prasugrel
administration and Verifynow assessment (82±36 and 88±51 minutes, respectively,
p=0.97). Nevertheless, overall prasugrel responsiveness was suboptimal in STEMI
patients and lower than in NSTEMI patients, with median PRU of 263[197-291] versus
69[46-118], respectively (p<0.00001). In STEMI group, 64.4% had PRU>235 versus
20% in NSTEMI group (p<0.003). We confirmed STEMI patients were good prasugrel
responder, in a chronic phase, more than 30 days after the first test, with median PRU
of 85[47-126]. In STEMI group, no parameter was found to be significantly correlated
to this slow responsiveness to prasugrel; there was a trend with morphine use (OR=
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